Diagnostic performance of aPS/PT antibodies in neuropsychiatric lupus and cardiovascular complications of systemic lupus erythematosus

Ramirez, Giuseppe A.; Canti, Valentina; Rosso, Stefania Del; Erra, Roberta; Moiola, Lucia; Magnoni, Marco; Bozzolo, Enrica; Manfredi, Angelo A.; Rovere‐Querini, Patrizia

doi:10.1080/08916934.2019.1696778

Cited by 13 publications

(6 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 42 ] Italy Prospective cohort study All patients met more than 4 criteria for SLE per ACR and had clinical manifestations of lupus nephritis NR SLE NA 173 months Medium Subgroups: § aPL Ramirez et al. [ 43 ] Italy Prospective cohort study All patients with SLE met the revised ACR or the 2012 SLICC classification criteria NR SLE NA 1.8 years Medium Reddy and Chand (2014)[ 44 ] India Prospective cohort study Patients who fulfilled the ACR criteria NR Subgroups: NA < 1 year to 4 years Low § With APS § Without APS Regéczy et al. [ 45 ] Hungary Retrospective cohort study Patients with SLE and with or without FV Leiden mutation NR Subgroups: NA 11 years High § Heterozygous FV § Normal FV § Heterozygous FV, aPL+ § Heterozygous FV, aPL− § Normal FV, aPL+ § Normal FV, aPL− Romero-Díaz et al.…”

Section: Resultsmentioning

confidence: 99%

Systematic Literature Review and Meta-analysis of Venous Thromboembolism Events in Systemic Lupus Erythematosus

et al. 2022

View full text Add to dashboard Cite

The objective of this work was to conduct a systematic literature review (SLR) and metaanalysis (MA) to evaluate the relative risk (RR) of venous thromboembolism (VTE) events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients with systemic lupus erythematosus (SLE) compared with patients without SLE, as well as the absolute risk (AR) (measured by incidence proportion) and incidence rate (IR) of VTE events in patients with SLE. The SLR was conducted using Embase, MEDLINE, and MEDLINE In-Process to identify observational studies evaluating the risk of VTE, DVT, and PE events in adult patients with SLE compared with the general population, published January 2000 to September 2020. Random-effects models were used as the primary approach in the MA. Heterogeneity was assessed on the basis of the I 2 value. Sensitivity analyses were performed to assess the robustness of results to various conditions, and subgroup analysis was performed for the AR of VTE by antiphospholipid status (aPLs) and antiphospholipid syndrome (APS). Of the 50 publications included for data extraction, 44 contained data for consideration in the MA of any one of the measures of interest (RR, AR, or IR) for VTE, DVT, or PE. The pooled RR indicates statistically significantly higher risk of VTE (RR 4.38, 95% confidence interval 2.63-7.29) in patients with SLE compared with the general population. Considerable heterogeneity was present in nearly all MA (I 2 = 75-100%). Moreover, a higher pooled AR of VTE was estimated in patients with SLE with aPLs (n/N = 0.13) and APS (n/N = 0.63) compared with patients with SLE without aPLs/APS (n/N = 0.07). Overall, there was evidence of an increased risk of VTE, DVT, and PE in patients with SLE compared with the general population.

show abstract

Section: Resultsmentioning

confidence: 99%

Systematic Literature Review and Meta-analysis of Venous Thromboembolism Events in Systemic Lupus Erythematosus

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Accelerated atherosclerosis is a major cause of morbidity and mortality in SLE patients [ 4 , 5 ]. Risk factors for atherosclerosis in SLE include inflammatory mediators, steroid therapy, and renal injury [ 3 , 6 , 7 ].…”

Section: Discussionmentioning

confidence: 99%

“…Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease with a wide spectrum of clinical manifestations, mainly involving kidneys, joints, skin, nervous system and blood [ 1 , 2 ]. SLE is one of the strongest known risk factors of cardiovascular diseases [ 3 – 5 ]. The atherosclerosis is the main etiology of most cardiovascular diseases [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Mesenchymal stem cell transplantation alleviated atherosclerosis in systemic lupus erythematosus through reducing MDSCs

Yao

et al. 2022

Stem Cell Res Ther

View full text Add to dashboard Cite

Objective The mechanism by which mesenchymal stem cell (MSC) transplantation alleviates atherosclerosis in systemic lupus erythematosus (SLE) remains elusive. In this study, we aim to explore the efficacy and mechanism of MSC in ameliorating atherosclerosis in SLE. Methods ApoE−/− and Fas−/− mice on the B6 background were cross-bred to generate SLE mice with atherosclerosis. Myeloid-derived suppressor cells (MDSCs) were sorted and quantified. The apoE−/−Fas−/− mice were either treated with anti-Gr antibody or injected with MDSCs. The lupus-like autoimmunity and atherosclerotic lesions were evaluated. Furthermore, the apoE−/−Fas−/− mice were transplanted with MSCs and lupus-like autoimmunity and atherosclerotic lesions were assessed. Results MDSCs in peripheral blood, spleen, draining lymph nodes increased in apoE−/−Fas−/− mice compared with B6 mice. Moreover, the adoptive transfer of MDSCs aggravated both atherosclerosis and SLE pathologies, whereas depleting MDSCs ameliorated those pathologies in apoE−/−Fas−/− mice. MSC transplantation in apoE−/−Fas−/− mice decreased the percentage of MDSCs, alleviated the typical atherosclerotic lesions, including atherosclerotic lesions in aortae and liver, and reduced serum cholesterol, triglyceride and low-density lipoprotein levels. MSC transplantation also reduced SLE pathologies, including splenomegaly, glomerular lesions, anti-dsDNA antibody in serum, urine protein and serum creatinine. Moreover, MSC transplantation regulated the generation and function of MDSCs through secreting prostaglandin E 2 (PGE2). Conclusion Taken together, these results indicated that the increased MDSCs contributed to atherosclerosis in SLE. MSC transplantation ameliorated the atherosclerosis and SLE through reducing MDSCs by secreting PGE2. Graphical Abstract

show abstract

“…Furthermore, in recent years the role of aPS/PT, currently considered a non-criteria aPL antibody, was highlighted and particularly in relation to the presence of lupus anticoagulants and neurologic manifestations. 33,34 Taken together, it seems that further studies should include a broad spectrum of criteria as well as noncriteria aPL (including aPS/PT) in order to substantialize the association.…”

Section: Discussionmentioning

confidence: 99%

Antiphospholipid antibodies may be associated with uveitis

Shapira

Ben-Arie-Weintrob

Gilburd

et al. 2020

European Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose: To evaluate the prevalence of a spectrum of autoantibodies in adult patients with non-infectious uveitis compared to healthy controls. Methods: This is a case-control study conducted in a tertiary referral center. Serum positivity to auto-antibodies directed at membranous phospholipids (aPL), nuclear antigens, and cytoplasmic (ANCA) antigens were assessed in sera from 63 non-infectious uveitis patients, and 78 healthy controls. Uveitis patients’ demographic and clinical data were collected retrospectively from their medical charts. Results: Of the spectrum of antibodies evaluated only aPL were linked with uveitis (OR 11.2, CI 1.4–92.1), as 13 (20.6%) uveitis patients were positive to at least one of the screened aPL, namely either anti-cardiolipin (aCL), anti-β2-glycoprotein (aβ2GPI), or anti-phosphatidylserine/prothrombin (aPS/PT). aCL antibodies were detected in 5/63 (7.9%) of uveitis patients and in none of controls ( p = 0.016). Positivity to either aCL or aβ2GPI was noted in 8/63 (12.7%) of uveitis patients and in 1 (1.3%) of the controls ( p = 0.011). Of the 13 uveitis patients positive to any of the aPL antibodies, 8 (62%) had exclusively anterior uveitis, 9 (69%) were idiopathic, and none had evidence of posterior vaso-occlusive involvement or systemic thrombotic manifestations. Conclusion: An association between aPL and uveitis among an unselected population of patients with no evidence of thrombosis or presence of the antiphospholipid syndrome was documented in this study. This link was observed, alike the general population of uveitis patients, mainly in patients with anterior eye inflammation. A possible interaction between aPL and uveitis, mediated by non-thrombotic mechanisms, requires further studies.

show abstract

Diagnostic performance of aPS/PT antibodies in neuropsychiatric lupus and cardiovascular complications of systemic lupus erythematosus

Cited by 13 publications

References 46 publications

Systematic Literature Review and Meta-analysis of Venous Thromboembolism Events in Systemic Lupus Erythematosus

Systematic Literature Review and Meta-analysis of Venous Thromboembolism Events in Systemic Lupus Erythematosus

Mesenchymal stem cell transplantation alleviated atherosclerosis in systemic lupus erythematosus through reducing MDSCs

Antiphospholipid antibodies may be associated with uveitis

Contact Info

Product

Resources

About